Kyntra Bio, Inc. (NASDAQ: KYNB) — Healthcare · Share Price, Chart & Market Data
About: Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $7.14 (+1.84%)
KYNBKyntra Bio, Inc.
Loading watchlist status…
Trade KYNB now
Kyntra Bio, Inc. share price
KYNB price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 7:30 am GMT+0
KYNB price performance
-2.725%
5D
5.778%
1M
-22.052%
YTD
2,131.25%
1Y
KYNB price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
NASDAQ rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 7:30 am GMT+0
KYNB details
KYNB Market Signals